The Clinical Impact of Low Doses of Dasatinib in Patients with Chronic Myeloid Leukemia

Basit Öğe Kaydı
dc.authoridKelkitli, Engin/0000-0001-7342-1760
dc.authoridDemirkan, Fatih/0000-0002-1172-8668
dc.authoridSahin, Fahri/0000-0001-9315-8891
dc.authoridPaydas, Semra/0000-0003-4642-3693
dc.authoridHaznedaroglu, Ibrahim C./0000-0001-8028-9462
dc.authorwosidSaydam, Guray/W-3827-2017
dc.authorwosidKelkitli, Engin/AAC-3607-2019
dc.authorwosidDemirkan, Fatih/AAD-6403-2019
dc.authorwosidSahin, Fahri/AAA-2768-2020
dc.authorwosidPaydas, Semra/F-3132-2018
dc.authorwosidHaznedaroglu, Ibrahim C./AAB-2114-2019
dc.contributor.authorAksu, Salih
dc.contributor.authorSahin, Fahri
dc.contributor.authorUz, Burak
dc.contributor.authorYavuz, Selim A.
dc.contributor.authorAtay, Hilmi
dc.contributor.authorKelkitli, Engin
dc.contributor.authorTurgut, Mehmet
dc.date.accessioned2024-06-12T10:56:30Z
dc.date.available2024-06-12T10:56:30Z
dc.date.issued2012
dc.departmentTrakya Üniversitesien_US
dc.description.abstractWe report our experience in 41 patients with chronic phase (CF)-chronic myeloid leukemia (CML) who had discontinued imatinib switched to dasatinib, retrospectively. The CF-CML patients received dasatinib at starting dose of 100 once daily. Dose adjustment were observed in 11 patients, respectively. In case of other circumstances, treatment has been continued with a lower dose if needed. The median dose of dasatinib was 100 mg daily (range: 50 to 140 mg). We conclude that even low-dose dasatinib therapy is an effective and safe in second line treatment of CML patients patients.en_US
dc.identifier.doi10.4999/uhod.12004
dc.identifier.endpage14en_US
dc.identifier.issn1306-133X
dc.identifier.issue1en_US
dc.identifier.startpage8en_US
dc.identifier.urihttps://doi.org/10.4999/uhod.12004
dc.identifier.urihttps://hdl.handle.net/20.500.14551/19805
dc.identifier.volume22en_US
dc.identifier.wosWOS:000306389200002en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.language.isoenen_US
dc.publisherAkad Doktorlar Yayinevien_US
dc.relation.ispartofUhod-Uluslararasi Hematoloji-Onkoloji Dergisien_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectChronic Myeloid Leukemiaen_US
dc.subjectDasatiniben_US
dc.subjectTreatment Dosageen_US
dc.subjectChronic Myelogenous Leukemiaen_US
dc.subjectTyrosine Kinase Inhibitoren_US
dc.subjectNilotinib Formerly Amn107en_US
dc.subjectChronic-Phaseen_US
dc.subjectBcr-Ablen_US
dc.subjectImatinib Resistanceen_US
dc.subjectTherapyen_US
dc.subjectFailureen_US
dc.subjectNonadherenceen_US
dc.subjectIntoleranceen_US
dc.titleThe Clinical Impact of Low Doses of Dasatinib in Patients with Chronic Myeloid Leukemiaen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu